Skip to main content

Zanubrutinib Disease Interactions

There are 6 disease interactions with zanubrutinib:

Moderate

Zanubrutinib (applies to zanubrutinib) arrhythmias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypertension, Infection - Bacterial/Fungal/Protozoal/Viral, Heart Disease

Atrial fibrillation and atrial flutter have occurred in patients treated with zanubrutinib monotherapy. Care should be exercised when using this agent in patients with cardiac risk factors, hypertension, and acute infections as they may be at increased risk of cardiac arrhythmias. It is recommended to monitor for signs and symptoms of atrial fibrillation and atrial flutter and manage as appropriate.

Moderate

Zanubrutinib (applies to zanubrutinib) bleeding

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect, Lymphoma

Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with zanubrutinib. These complications have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Special care should be taken when this agent is co-administered with antiplatelet or anticoagulant medications as it may further increase the risk of hemorrhage. It is recommended to monitor for signs and symptoms of bleeding and to discontinue zanubrutinib if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding treatment for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Moderate

Zanubrutinib (applies to zanubrutinib) cytopenias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Cytopenias, including neutropenia, thrombocytopenia, and anemia were reported in patients treated with zanubrutinib. Care should be taken when using this agent in patients with hematological abnormalities. It is recommended to monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.

Moderate

Zanubrutinib (applies to zanubrutinib) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The safety of zanubrutinib has not been evaluated in patients with severe hepatic impairment. Dosage modification of zanubrutinib is recommended in patients with severe hepatic impairment. The recommended dose for patients with severe hepatic impairment is 80 mg orally twice daily. No dosage modification is recommended in patients with mild to moderate hepatic impairment. Monitor for adverse reactions in patients with hepatic impairment.

Moderate

Zanubrutinib (applies to zanubrutinib) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Fatal and serious infections including bacterial, viral, or fungal and opportunistic infections have occurred in patients with hematological malignancies treated with zanubrutinib. Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

Moderate

Zanubrutinib (applies to zanubrutinib) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The effect of severe renal impairment (CrCl < 30 mL/min) and dialysis on zanubrutinib pharmacokinetics is unknown. It is recommended to monitor for adverse reactions these patient populations. No dosage modification is recommended in patients with mild to moderate renal impairment (CrCl > 30 mL/min, estimated by Cockroft-Gault).

Zanubrutinib drug interactions

There are 368 drug interactions with zanubrutinib

Zanubrutinib alcohol/food interactions

There are 2 alcohol/food interactions with zanubrutinib

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.